BioNTech Results Presentation Deck
Second Quarter 2020 Financial Results (unaudited) - Profit and Loss
(in millions) ¹
Revenues resulting from collaboration and license
agreements
Revenues from other sales transactions
Total revenues
25
Cost of sales
Gross profit
Research and development expenses
Sales and marketing expenses
General and administrative expenses
Other operating income less expenses
Finance income less expenses
Income taxes
Loss for the period
1 Due to rounding, numbers presented may not add up precisely to the totals.
Three months ended
June 30,
2019
€ 20.1
5.7
€ 25.8
2020
€ 32.6
9.2
€ 41.8
(5.7)
€ 36.1
(95.2)
(3.0)
(18.8)
0.0
(9.6)
2.2
€ (88.3)
(5.5)
€ 20.3
(53.4)
(0.7)
(14.6)
0.5
(2.2)
0.0
€ (50.1)
Six months ended
June 30,
2019
€ 42.0
9.9
€ 51.9
2020
€ 53.7
15.7
€ 69.4
(11.5)
€ 57.9
(160.3)
(3.5)
(34.6)
0.3
(3.7)
2.2
€ (141.7)
(8.7)
€ 43.2
(110.6)
(1.2)
(23.9)
0.8
0.9
0.0
€ (90.8)
BIONTECHView entire presentation